Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 10/20 | 0.41 |
| ▸ | FNTB | P49356 | 10/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289601 | 0.91 | L3MBTL1 (0.41) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL2551044 | 0.90 | RXFP1 (0.52) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL1922242 | 0.87 | L3MBTL1 (0.40) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL2553694 | 0.86 | RXFP1 (0.53) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL4382831 | 0.85 | ALDH1A1 (0.37) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL2228571 | 0.84 | L3MBTL1 (0.37) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL18430411 | 0.82 | L3MBTL1 (0.54) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL516264 | 0.81 | PLA2G1B (0.41) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL2554376 | 0.80 | L3MBTL1 (0.74) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL1922260 | 0.78 | PLA2G1B (0.43) | L3MBTL1RXFP1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011124992-A1 | SUBSTANTIALLY PURE STRONTIUM RANELATE | ACTAVIS GROUP PTC EHF (IS) | 2011-10-13 | — | — | WO | claimed |
| WO-2013113319-A1 | PROCESS FOR THE PREPARATION OF STRONTIUM RANELATE, INTERMEDIATE OR HYDRATES THEREOF | PHARMATHEN S.A. (GR) | 2013-08-08 | — | — | WO | disclosed |
| WO-2012163309-A1 | STABLE CRYSTALLINE FORM X OF STRONTIUM RANELATE | ZENTIVA, K.S. (CZ) | 2012-12-06 | — | — | WO | disclosed |
| US-8063100-B2 | Process for the synthesis of strontium ranelate and its hydrates | LES LABORATOIRES SERVIER (FR) | 2011-11-22 | — | — | US | disclosed |
| WO-2011124992-A1 | SUBSTANTIALLY PURE STRONTIUM RANELATE | ACTAVIS GROUP PTC EHF (IS) | 2011-10-13 | — | — | WO | disclosed |
| US-20090082578-A1 | Process for the synthesis of strontium ranelate and its hydrates | LES LABORATOIRES SERVIER (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082578-A1 | Process for the synthesis of strontium ranelate and its hydrates | STAU1, RANBP1, RAN | L3MBTL1 4713/4885RXFP1 3204/4885ALDH1A1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.